Radezolid is primarily used as an antibiotic to treat infections caused by Gram-positive bacteria, including complicated skin and soft tissue infections as well as lower respiratory tract infections such as pneumonia. It is particularly effective against drug-resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus pneumoniae. The compound works by inhibiting bacterial protein synthesis, making it a valuable option for treating these conditions. Its unique mechanism of action reduces the likelihood of cross-resistance with other antibiotics, enhancing its utility in clinical settings. Radezolid is often considered when first-line treatments fail or are unsuitable due to resistance or patient-specific factors. Ongoing research explores its potential in treating other bacterial infections and its efficacy in combination therapies.